Skip to main content

Fiscal Wizard · Single-issue tearsheet

SNY / Jun 21, 2026 Run #7289

SNY

Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Composite verdict

F 26.1 / 100
Bearish setup · Trend Following 13 drivers · 4 gates blocking
  • Parabolic SAR Flip
  • SuperTrend
  • MACD Signal Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 13th of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: volatile range
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 4Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -11%
Asset value $29.82Earnings power value $31.73Price $42.38

Priced above its no-growth earnings power value ($31.73/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

52.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Total Shareholder Yield 100
Inventory Turnover 0
Dividend Yield 93
Cash Conversion Cycle 0
Free Cash Flow Yield 87
Payout Ratio 24

Technicals Bearish

0.0 / 100

Bearish setup leads (Parabolic SAR Flip, SuperTrend, MACD Signal Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 8
SuperTrend 9
MACD Signal Cross 12

Risk Gates

4 blocking 2 caution

4 guards active, 19 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SNY.